Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a steroid and exercise beat cancer fatigue?

NCT ID NCT03583255

Symptom relief Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study tests whether adding the steroid dexamethasone to a physical activity program helps reduce severe fatigue in people with advanced cancer. About 99 participants will take the drug or a placebo while doing strength and walking exercises. The goal is to see if the combination is feasible and improves fatigue more than exercise alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dexamethasone (a steroid that reduces inflammation)
What this could lead to
If successful, this could offer a new way to ease severe fatigue in people with advanced cancer, improving their daily quality of life.
What could go wrong
This is a mid-stage trial with only 99 participants, so results may not apply to everyone. Dexamethasone has side effects like increased appetite, mood changes, and risk of infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

99 people

The number who actually took part.

Started

Jun 2018

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of locally advanced cancer (defined as metastatic or recurrent cancer or completed 2 lines of therapy) with fatigue \>= 4/10 (0-10 scale) on the Edmonton Symptom Assessment Scale (ESAS) * Presence of fatigue for at least 2 weeks * Normal cognition defined as Memorial Delirium Assessment Scale (MDAS) of =\< 13/30 completed in person or via video conference * Hemoglobin \> 8 g/L within 2 weeks of enrollment in the study * Zubrod performance status =\< 2 * Life expectancy of \>= 4 months * Able to read, write, and speak English Exclusion Criteria: * Patients with a history of hypersensitivity to dexamethasone or having any contraindication to physical activity as determined by the treating physician * Reports of a fall in the past 30 days * Uncontrolled diabetes mellitus as defined by a random blood sugar of \> 200 mg/dl not being monitored by their primary care physician * Sepsis and/or acute, chronic, or ongoing infections that are currently being treated with systemic antimicrobials * Current, active peptic ulcer disease * Neutropenia as defined by an absolute neutrophil count (ANC) of \< 1000 cells/mm * Regular participation in moderate- or vigorous-intensity physical activity for \>= 30 minutes at least 5 times a week and strength training for \>= 2 days * Symptomatic cardiac disease (New York Heart Association functional class III or IV) or coronary artery disease * Patients currently on immunotherapy * Inability to comply with study protocol procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced malignant solid neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer hematopoietic and lymphoid system neoplasm metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced malignant solid neoplasm Hematopoietic and lymphoid system neoplasm Locally advanced malignant solid neoplasm Metastatic malignant solid neoplasm Recurrent malignant solid neoplasm

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.